Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.
- H. Lokhorst, T. Plesner, +18 authors P. Richardson
- The New England journal of medicine
- 23 September 2015
BACKGROUND Multiple myeloma cells uniformly overexpress CD38. We studied daratumumab, a CD38-targeting, human IgG1κ monoclonal antibody, in a phase 1-2 trial involving patients with relapsed myeloma… Expand
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
- P. Moreau, T. Masszi, +23 authors P. Richardson
- The New England journal of medicine
- 27 April 2016
BACKGROUND Ixazomib is an oral proteasome inhibitor that is currently being studied for the treatment of multiple myeloma. METHODS In this double-blind, placebo-controlled, phase 3 trial, we… Expand
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised,…
BACKGROUND Panobinostat is a potent oral pan-deacetylase inhibitor that in preclinical studies has synergistic anti-myeloma activity when combined with bortezomib and dexamethasone. We aimed to… Expand
Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma.
In this double-blind, placebo-controlled study, 363 patients with untreated multiple myeloma were randomized to receive either melphalan-prednisone and thalidomide (MPT) or melphalan-prednisone and… Expand
Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN).
Most patients with newly diagnosed multiple myeloma (MM) are aged > 65 years with 30% aged > 75 years. Many elderly patients are also vulnerable because of comorbidities that complicate the… Expand
An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma.
AIM To test the reliability, validity and sensitivity of the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-MY24 questionnaire, designed to assess the quality of life of… Expand
Cerebral and meningeal multiple myeloma after autologous stem cell transplantation. A case report and review of the literature
Meningeal involvement of multiple myeloma is a very rare complication. Defining meningeal myelomatosis (MeM) as the presence of plasma cells in the cerebrospinal fluid in a patient with multiple… Expand
Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials.
The role of thalidomide for previously untreated elderly patients with multiple myeloma remains unclear. Six randomized controlled trials, launched in or after 2000, compared melphalan and prednisone… Expand
Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Daratumumab, a human CD38 immunoglobulin G1 kappa (IgG1κ) monoclonal antibody, has activity as monotherapy in multiple myeloma (MM). This phase 1/2 study investigated daratumumab plus… Expand
Increased Level of both CD4+FOXP3+ Regulatory T Cells and CD14+HLA‐DR−/low Myeloid‐Derived Suppressor Cells and Decreased Level of Dendritic Cells in Patients with Multiple Myeloma
- M. Brimnes, A. Vangsted, +4 authors I. Svane
- Scandinavian journal of immunology
- 1 December 2010
Patients with multiple myeloma (MM) suffer from a general impaired immunity comprising deficiencies in humoral responses, T‐cell responses as well as dendritic cell (DC) function. Thus, to achieve… Expand